Company overview

Dermata Therapeutics is preparing to commercialize its Tome skincare products after shifting its focus from prescription-drug development to over-the-counter products. It has not yet generated operating revenue or launched a commercial product. Its first sales depend on launching and gaining customer acceptance for Tome Foundational Treatment, with Clearing Treatment for acne planned to follow.

Consumers would buy primarily through Dermata’s own online store, while skincare professionals, including dermatology practices and medical spas, would buy products for their customers. The planned Clearing Treatment combines salicylic acid wipes with Bioneedle treatments, with discounted subscriptions intended to encourage refill purchases. Bioneedles come from processed sponge powder and create tiny channels in the skin.

Dermata relies on outside manufacturers and on Russia-based Reka-Farm as its sole supplier of the Spongilla sponge raw material; no alternative supplier it evaluated met its manufacturing-quality standards. Its planned over-the-counter acne kit must meet FDA requirements to be sold without separate drug approval. Dermata intends to classify Bioneedle and hydrogen peroxide as inactive ingredients with no therapeutic claims; an FDA decision that they are active ingredients could require reformulation. Until product sales can support operations, the company depends on outside funding, historically mainly equity financing.